AWY0 Stock Chart & Stats
€0.03
<€0.01(3.23%)
At close: 4:00 PM EST
€0.03
<€0.01(3.23%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€2.78M
Enterprise Value€2.08
Total Cash (Recent Filing)€4.46M
Total Debt (Recent Filing)€10.68K
Price to Earnings (P/E)―
Beta12.48
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,522,412,700
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€522.61K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt relative to equity provides a durable solvency cushion that reduces near-term default risk and preserves access to borrowing or partnership options. This structural conservatism gives management flexibility to finance R&D or delay dilutive funding events.
Focused Clinical-stage R&D ExpertiseA tightly focused pipeline in neuromuscular and neurological indications concentrates technical expertise and regulatory know-how. This specialization can improve trial design, speed decision-making, and supports potential value creation from clinical milestones or strategic partnerships over months to years.
Losses Largely Cash-backedReported losses translate into actual cash consumption rather than hidden noncash charges, making cash needs more predictable. That clarity improves cash planning and helps management evaluate financing timelines and partnership or licensing strategies with clearer funding forecasts.
Bears Say
Pre-revenue With Widening Operating LossesSustained pre-revenue status combined with materially widening losses means long reliance on external funding and clinical success to create value. Over 2-6 months this structural reality increases execution and financing risk and limits ability to self-fund R&D progress.
Accelerating Cash Burn And Negative Free Cash FlowSteepening free cash flow deficits amplify the urgency of financing or partnering, raising the probability of equity dilution or hurried deals. Structurally higher cash consumption constrains runway and strategic optionality absent durable revenue or sizable external funding.
Eroding Shareholder EquityA halving of equity in three years reflects persistent losses and value erosion, weakening the balance sheet buffer. This reduces capacity for secured borrowing, limits negotiating leverage with partners, and increases vulnerability to adverse funding market conditions.
Percheron Therapeutics News
AWY0 FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is €2.78M.
When is Percheron Therapeutics’s upcoming earnings report date?
Percheron Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 25 days.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Feb 26, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Overvalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,522,412,700 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in DE:AWY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:AWY0 Sentiment 92%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.52%
Trailing 12-Months
Company Description
Percheron Therapeutics
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Cronos Australia Ltd.
―